scholarly journals Predictors of Time to Relapse/Recurrence after Electroconvulsive Therapy in Patients with Major Depressive Disorder: A Population-Based Cohort Study

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Axel Nordenskjöld ◽  
Lars von Knorring ◽  
Ingemar Engström
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Electroconvulsive Therapy ◽  
Substance Dependence ◽  
Population Based ◽  
Major Depressive ◽  
Quality Register ◽  
Increased Risk ◽  
One Year ◽  
Risk Of Relapse

Objective. The aim of the study is to define predictors of relapse/recurrence after electroconvulsive therapy, ECT, for patients with major depressive disorder.Methods. A study of all patients (n=486) treated by means of ECT for major depressive disorder was performed. The data were derived from a regional quality register in Sweden. Psychiatric hospitalisation or suicide was used as a marker for relapse/recurrence.Results. The relapse/recurrence rate within one year after ECT was 34%. Factors associated with increased risk of relapse/recurrence included comorbid substance dependence and treatment with benzodiazepines or antipsychotics during the follow-up period.Conclusions. Within the first years after ECT, relapses/recurrences leading to hospitalisation or suicide are common. Treatment with lithium might be beneficial, while benzodiazepines, antipsychotics, or continuation ECT does not seem to significantly reduce the risk of relapse/recurrence.

Increased risk of hypothyroidism and hyperthyroidism in patients with major depressive disorder: A population-based study

2013 ◽  
Vol 74 (3) ◽  
pp. 233-237 ◽  
Author(s):  
En-Liang Wu ◽  
I-Chia Chien ◽  
Ching-Heng Lin ◽  
Yiing-Jenq Chou ◽  
Pesus Chou
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Population Based ◽  
Major Depressive ◽  
Population Based Study ◽  
Increased Risk

Increased risk of major depressive disorder among probands with psoriasis and unaffected siblings: a nationwide population‐based study

2020 ◽  
Vol 34 (7) ◽  
pp. 1510-1515 ◽  
Author(s):  
Y.‐X. Dai ◽  
C.‐C. Chen ◽  
Y.‐H. Tai ◽  
Y.‐T. Chang ◽  
T.‐J. Chen ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Population Based ◽  
Major Depressive ◽  
Population Based Study ◽  
Increased Risk

scholarly journals Treatment patterns of patients diagnosed with major depressive disorder and suicidal ideation or attempt: a U.S. population-based study utilizing real-world data

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
David M. Kern ◽  
M. Soledad Cepeda ◽  
Frank Wiegand
Keyword(s):  
Major Depressive Disorder ◽  
Suicidal Ideation ◽  
Depressive Disorder ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Population Based ◽  
Treatment Patterns ◽  
Real World Data ◽  
Major Depressive ◽  
Multiple Treatment ◽  
One Year

Abstract Background There is a knowledge gap regarding the treatment patterns of patients with major depressive disorder (MDD) who experience suicidal ideation or a suicide attempt (SI/SA). Methods Patients with SI/SA were identified from a large US-based claims database covering 84 million lives, during 1/1/2014–3/31/2020. Patients with MDD were indexed at their first diagnosis for SI/SA and followed up to 365 days. Treatment patterns were captured at the class level and included procedures of electroconvulsive therapy and transcranial magnetic stimulation, and pharmacotherapy including selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, other antidepressants, anxiolytics, hypnotics/sedatives, antipsychotics, psychostimulants, and lithium. Results There were 42,204 MDD + SI/SA patients identified. In the year prior to the index event > 40% of individuals received an SSRI and more than one-third received an anxiolytic. Within 1 year following, 84.4% received ≥1 of the treatments of interest. Of those, 70.2% went on to a subsequent class-based regimen, 46.3% received a third, and 28.1% received ≥4. More than three-quarters of patients received multiple treatment classes simultaneously. SSRIs were the most common treatments during follow-up (61.9%), followed by other antidepressants (51.3%), anxiolytics (50.8%) and anticonvulsants (43.6%). Conclusions There was a large amount of variability and polypharmacy in the treatments received by MDD patients with SI/SA, and is much more complex than what has been previously observed in the general MDD population. Within one-year, many patients received four or more unique class-based regimens and most patients received treatments from multiple classes simultaneously, indicating the high unmet medical need and therapy refractoriness of this patient population.

Increased risk of hypertension in patients with major depressive disorder: A population-based study

2012 ◽  
Vol 73 (3) ◽  
pp. 169-174 ◽  
Author(s):  
En-Liang Wu ◽  
I-Chia Chien ◽  
Ching-Heng Lin ◽  
Yiing-Jenq Chou ◽  
Pesus Chou
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Population Based ◽  
Major Depressive ◽  
Population Based Study ◽  
Increased Risk

scholarly journals Predictors of diagnostic transition from major depressive disorder to bipolar disorder: a retrospective observational network study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Anastasiya Nestsiarovich ◽  
Jenna M. Reps ◽  
Michael E. Matheny ◽  
Scott L. DuVall ◽  
Kristine E. Lynch ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
External Validation ◽  
Severe Depression ◽  
Common Data Model ◽  
Major Depressive ◽  
National Network ◽  
Increased Risk ◽  
One Year

AbstractMany patients with bipolar disorder (BD) are initially misdiagnosed with major depressive disorder (MDD) and are treated with antidepressants, whose potential iatrogenic effects are widely discussed. It is unknown whether MDD is a comorbidity of BD or its earlier stage, and no consensus exists on individual conversion predictors, delaying BD’s timely recognition and treatment. We aimed to build a predictive model of MDD to BD conversion and to validate it across a multi-national network of patient databases using the standardization afforded by the Observational Medical Outcomes Partnership (OMOP) common data model. Five “training” US databases were retrospectively analyzed: IBM MarketScan CCAE, MDCR, MDCD, Optum EHR, and Optum Claims. Cyclops regularized logistic regression models were developed on one-year MDD-BD conversion with all standard covariates from the HADES PatientLevelPrediction package. Time-to-conversion Kaplan-Meier analysis was performed up to a decade after MDD, stratified by model-estimated risk. External validation of the final prediction model was performed across 9 patient record databases within the Observational Health Data Sciences and Informatics (OHDSI) network internationally. The model’s area under the curve (AUC) varied 0.633–0.745 (µ = 0.689) across the five US training databases. Nine variables predicted one-year MDD-BD transition. Factors that increased risk were: younger age, severe depression, psychosis, anxiety, substance misuse, self-harm thoughts/actions, and prior mental disorder. AUCs of the validation datasets ranged 0.570–0.785 (µ = 0.664). An assessment algorithm was built for MDD to BD conversion that allows distinguishing as much as 100-fold risk differences among patients and validates well across multiple international data sources.

scholarly journals 117 Impact of Antipsychotic Treatment Switching in Patients with Schizophrenia, Bipolar Disorder, and Major Depressive Disorder

CNS Spectrums ◽  
2020 ◽  
Vol 25 (2) ◽  
pp. 276-276
Author(s):  
Rajeev Ayyagari ◽  
Darren Thomason ◽  
Fan Mu ◽  
Michael Philbin ◽  
Benjamin Carroll
Keyword(s):  
Bipolar Disorder ◽  
Major Depressive Disorder ◽  
Side Effects ◽  
Depressive Disorder ◽  
Antipsychotic Treatment ◽  
Disease Relapse ◽  
Major Depressive ◽  
Study Objective ◽  
Increased Risk ◽  
Risk Of Relapse

Abstract:Study Objective:To evaluate the risk of relapse for patients with schizophrenia (SZ), bipolar disorder (BP), and major depressive disorder (MDD) who switched antipsychotics compared with those who did not switch.Background:Antipsychotics are commonly used for maintenance treatment of SZ, BP, and MDD but can have significant side effects, such as extrapyramidal symptoms (EPS). Adherence to treatment is important for reducing the risk of relapse, but fear of side effects may prompt medication switching.Methods:Medicaid claims from 6 US states spanning 6 years were retrospectively analyzed for antipsychotic switching versus non-switching. For all patients with SZ, BD or MDD and for the subset of patients who also had ≥1 EPS diagnosis during the baseline period, times to the following outcomes, during a 2-year study period were analyzed: underlying disease relapse, psychiatric relapse, all-cause emergency room (ER) visit, all-cause inpatient (IP) admission and EPS diagnosis.Results:Switchers (N=10,548) had a shorter time to disease relapse, other psychiatric relapse, IP admissions, ER visits, and EPS diagnosis (all, log-rank P<0.001) than non-switchers (N=31,644). Switchers reached the median for IP admission (21.50 months) vs non-switchers (not reached) and for ER visits (switchers, 9.07 months; non-switchers, 13.35 months). For disease relapse, other psychiatric relapse, and EPS diagnosis, <50% of patients had an event during the 2-year study period. Comparisons in a subgroup of patients with ≥1 EPS diagnosis revealed similar outcomes.Conclusions:These results show that disease and other psychiatric relapse, all-cause ER visits, IP admissions, and EPS diagnosis occurred earlier for switchers than for non-switchers, suggesting that switching is associated with an increased risk of relapse in patients with SZ, BP and MDD.Funding Acknowledgements:This study was supported by Teva Pharmaceuticals, Petach Tikva, Israel.

scholarly journals Increased Risk of Major Depressive Disorder After Cholecystectomy: A Nationwide Population-Based Cohort Study in Korea

2021 ◽  
Vol 12 (4) ◽  
pp. e00339
Author(s):  
Eun Hyo Jin ◽  
Kyungdo Han ◽  
Dong Ho Lee ◽  
Cheol Min Shin ◽  
Joo Hyun Lim ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Cohort Study ◽  
Depressive Disorder ◽  
Population Based ◽  
Major Depressive ◽  
Increased Risk

Increased risk of hyperlipidemia in patients with major depressive disorder: A population-based study

2013 ◽  
Vol 75 (3) ◽  
pp. 270-274 ◽  
Author(s):  
I-Chia Chien ◽  
Ching-Heng Lin ◽  
Yiing-Jenq Chou ◽  
Pesus Chou
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Population Based ◽  
Major Depressive ◽  
Population Based Study ◽  
Increased Risk
Sign in / Sign up

Export Citation Format

Share Document